Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 25654-31-3
2. 2-[(2e)-3,7-dimethylocta-2,6-dienyl]-5-pentylbenzene-1,3-diol
3. Chembl497318
4. Chebi:69477
5. Cannabigerol (cbg)
6. J1k406072n
7. 2808-33-5
8. Cbg
9. 1,3-benzenediol, 2-(3,7-dimethyl-2,6-octadienyl)-5-pentyl-, (e)-
10. Geranylolivetol
11. Unii-j1k406072n
12. Schembl144819
13. Schembl14764730
14. Gtpl11094
15. Resorcinol, 2-(3,7-dimethyl-2,6-octadienyl)-5-pentyl-
16. Dtxsid701014168
17. (e)-2-(3,7-dimethyl-2,6-octadienyl)-5-pentyl-1,3-benzenediol
18. 1,3-benzenediol, 2-(3,7-dimethyl-2,6-octadienyl)-5-pentyl-
19. Bcp23754
20. Ex-a5335
21. Zinc4217650
22. Bdbm50318487
23. Akos024457386
24. Db14734
25. Cannabigerol (1.0 Mg/ml In Methanol)
26. C20219
27. Cannabigerol (cbg) 100 Microg/ml In Methanol
28. F70893
29. Cannabigerol (cbg) 1000 Microg/ml In Methanol
30. Cannabigerol (cbg) 250 Microg/ml In Acetonitrile
31. Q412122
32. 2-(3,7-dimethyl-2,6-octadienyl)-5-pentylresorcinol
33. (e)-2-(3,7-dimethyl-2,6-octadienyl)-5-pentyl-resorcinol
34. 2-[(2e)-3,7-dimethyl-2,6-octadienyl)-5-pentyl-1,3-benzenediol
35. 2-[(2e)-3,7-dimethylocta-2,6-dienyl]-5-pentyl-benzene-1,3-diol
36. (e)-2-(3,7-dimethylocta-2,6-dien-1-yl)-5-pentylbenzene-1,3-diol
37. 2-[(2e)-3,7-dimethyl-2,6-octadienyl]-5-pentyl-1,3-benzenediol #
38. 2-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-5-pentylbenzene-1,3-diol
39. Resorcinol, 2-(3,7-dimethyl-2,6-octadienyl)-5-pentyl-, (e)-
40. 1,3-benzenediol, 2-((2e)-3,7-dimethyl-2,6-octadien-1-yl)-5-pentyl-
41. Cannabigerol Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material
Molecular Weight | 316.5 g/mol |
---|---|
Molecular Formula | C21H32O2 |
XLogP3 | 7.4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 9 |
Exact Mass | 316.240230259 g/mol |
Monoisotopic Mass | 316.240230259 g/mol |
Topological Polar Surface Area | 40.5 Ų |
Heavy Atom Count | 23 |
Formal Charge | 0 |
Complexity | 367 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
About the Company : Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout...
About the Company : We were founded a decade ago with a vision to make the best products available to all and to help humanity while we do it. From plant-sugars to anti-malarial drugs, our proprietary...
About the Company : Celadon Pharmaceuticals is a UK-based company specializing in the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Their primary focus is on...
About the Company : Celadon Pharmaceuticals is a UK-based company specializing in the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Their primary focus is on...
About the Company : At Embio, technology is the foundation of our success, driving leadership in every product we manufacture. With 30+ years of expertise in bacterial, fungal, and Category 1 GMO biot...
About the Company : Founded in 2018, Hempsana was borne out of the founders’ primary mission to provide comfort from ailments, and to be a part of the healing process, by providing a natural and con...
About the Company : MediPharm Labs is a full-service pharmaceutical company that specializes in producing and manufacturing high-quality, purified cannabinoid-based derivatives and pharmaceutical ingr...
About the Company : NINGBO INNO PHARMCHEM CO.,LTD. develop, pilot and commercial produce organic chemicals, pharmaceutical intermediates and nutraceuticals. We also offer custom synthesis and manufact...
About the Company : Phytoplant Research S.L. is a privately-owned Spanish company founded in 2008 and active in the field of phytotherapy research. The company specializes in developing the industria...
About the Company : We are an elite team of scientists and business leaders pioneering how synthetic biology can bring the best of nature’s ingredients to market. Willow Biosciences is a biotechnolo...
Details:
The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.
Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol
Therapeutic Area: Neurology Brand Name: RHO Phyto
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: $0.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 04, 2023
Lead Product(s) : Cannabidiol,Cannabigerol,Tetrahydrocannabinol
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $0.8 million
Deal Type : Private Placement
Avicanna Announces Closing of Non-Brokered Private Placement
Details : The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying r...
Product Name : RHO Phyto
Product Type : Small molecule
Upfront Cash : Undisclosed
December 04, 2023
Details:
The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.
Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol
Therapeutic Area: Neurology Brand Name: RHO Phyto
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: $1.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 02, 2023
Lead Product(s) : Cannabidiol,Cannabigerol,Tetrahydrocannabinol
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $1.4 million
Deal Type : Private Placement
Avicanna Announces Closing of Non-Brokered Private Placement of Debenture Units
Details : The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying r...
Product Name : RHO Phyto
Product Type : Small molecule
Upfront Cash : Undisclosed
August 02, 2023
Details:
The collaboration aims to focus on Avicanna’s proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.
Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol
Therapeutic Area: Neurology Brand Name: RHO Phyto
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Applied Research Centre at Langara College
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 13, 2023
Lead Product(s) : Cannabidiol,Cannabigerol,Tetrahydrocannabinol
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Applied Research Centre at Langara College
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to focus on Avicanna’s proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios...
Product Name : RHO Phyto
Product Type : Small molecule
Upfront Cash : Undisclosed
June 13, 2023
Details:
Through the license and supply agreement, the South American pharmaceutical company will license Avicanna’s intellectual property and supply finished pharmaceutical products starting initially with its proprietary 10% cannabidiol oral preparation, marketed under the RHO Phyto.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol,Cannabigerol
Therapeutic Area: Neurology Brand Name: Rho Phyto
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 13, 2022
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol,Cannabigerol
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $1.0 million
Deal Type : Licensing Agreement
Details : Through the license and supply agreement, the South American pharmaceutical company will license Avicanna’s intellectual property and supply finished pharmaceutical products starting initially with its proprietary 10% cannabidiol oral preparation, mark...
Product Name : Rho Phyto
Product Type : Small molecule
Upfront Cash : Undisclosed
April 13, 2022
Details:
New CBG products include Advanced Formula, which is a CBG:CBD 1:2 oil, and Northbound, which is a high CBG vape cartridge with CBD inspired by The White and Appalachia strains.
Lead Product(s): Cannabigerol,Cannabidiol
Therapeutic Area: Neurology Brand Name: CBG:CBD
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Lead Product(s) : Cannabigerol,Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products
Details : New CBG products include Advanced Formula, which is a CBG:CBD 1:2 oil, and Northbound, which is a high CBG vape cartridge with CBD inspired by The White and Appalachia strains.
Product Name : CBG:CBD
Product Type : Small molecule
Upfront Cash : Not Applicable
April 05, 2022
Details:
Naturally derived oil and inhalable cannabigerol (cannabinoid) products added to MediPharm's wellness portfolio – the benefits of CBG without the effects of THC.
Lead Product(s): Cannabidiol,Cannabigerol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Lead Product(s) : Cannabidiol,Cannabigerol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products
Details : Naturally derived oil and inhalable cannabigerol (cannabinoid) products added to MediPharm's wellness portfolio – the benefits of CBG without the effects of THC.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
April 05, 2022
Details:
According to the research by Oregon state university Hemp Comound, Cannabigerolic Acid has a good safety profile in humans and are effective against variants of SARS-CoV-2 including variant.
Lead Product(s): Cannabigerol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2022
Lead Product(s) : Cannabigerol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Oregon State Research Shows Hemp Compounds Prevent Coronavirus From Entering Human Cells
Details : According to the research by Oregon state university Hemp Comound, Cannabigerolic Acid has a good safety profile in humans and are effective against variants of SARS-CoV-2 including variant.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
January 10, 2022
Details:
HUM-234 was shown to prevent weight gain in mice fed a high fat diet, and importantly abrogated the development of fatty liver (steatosis), a condition clinically associated with multiple metabolic disorders, including diabetes and obesity and a precursor to liver fibrosis.
Lead Product(s): Cannabigerol
Therapeutic Area: Neurology Brand Name: HUM-234
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2021
Lead Product(s) : Cannabigerol
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : HUM-234 was shown to prevent weight gain in mice fed a high fat diet, and importantly abrogated the development of fatty liver (steatosis), a condition clinically associated with multiple metabolic disorders, including diabetes and obesity and a precurso...
Product Name : HUM-234
Product Type : Small molecule
Upfront Cash : Not Applicable
October 26, 2021
Details:
The programs include in-vitro study of thin film delivery of cannabigerol and quercetin for potential anti-bacterial and anti-viral treatments as well as development of point-of-care sensor-film.
Lead Product(s): Cannabigerol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2020
Lead Product(s) : Cannabigerol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
XPhyto Therapeutics Initiates Infectious Disease Programs
Details : The programs include in-vitro study of thin film delivery of cannabigerol and quercetin for potential anti-bacterial and anti-viral treatments as well as development of point-of-care sensor-film.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
March 03, 2020
Regulatory Info :
Registration Country : Canada
Brand Name :
Dosage Form : Sweet Gummy
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Canada
Packaging :
Regulatory Info :
Dosage : Sweet Gummy
Dosage Strength : 5MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Canada
Regulatory Info :
Registration Country : U.S.A
Brand Name : VESIsorb
Dosage Form : Softgel
Dosage Strength :
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : U.S.A
Packaging :
Regulatory Info :
Dosage : Softgel
Dosage Strength :
Brand Name : VESIsorb
Approval Date :
Application Number :
Registration Country : U.S.A
Market Place
ABOUT THIS PAGE
94
PharmaCompass offers a list of Cannabigerol API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cannabigerol manufacturer or Cannabigerol supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cannabigerol manufacturer or Cannabigerol supplier.
PharmaCompass also assists you with knowing the Cannabigerol API Price utilized in the formulation of products. Cannabigerol API Price is not always fixed or binding as the Cannabigerol Price is obtained through a variety of data sources. The Cannabigerol Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cannabigerol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cannabigerol, including repackagers and relabelers. The FDA regulates Cannabigerol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cannabigerol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cannabigerol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cannabigerol supplier is an individual or a company that provides Cannabigerol active pharmaceutical ingredient (API) or Cannabigerol finished formulations upon request. The Cannabigerol suppliers may include Cannabigerol API manufacturers, exporters, distributors and traders.
click here to find a list of Cannabigerol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Cannabigerol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cannabigerol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cannabigerol GMP manufacturer or Cannabigerol GMP API supplier for your needs.
A Cannabigerol CoA (Certificate of Analysis) is a formal document that attests to Cannabigerol's compliance with Cannabigerol specifications and serves as a tool for batch-level quality control.
Cannabigerol CoA mostly includes findings from lab analyses of a specific batch. For each Cannabigerol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cannabigerol may be tested according to a variety of international standards, such as European Pharmacopoeia (Cannabigerol EP), Cannabigerol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cannabigerol USP).